Company Overview

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

  • Name

    West Pharmaceutical Services, Inc.

  • CEO

    Mr. Eric M. Green

  • Website

    www.westpharma.com

  • Sector

    Life Sciences Tools and Services

  • Year Founded

    1923

Profile

  • Market Cap

    $22.17B

  • EV

    $22.03B

  • Shares Out

    72.54M

  • Revenue

    $2,876.9M

  • Employees

    10,600

Margins

  • Gross

    35.68%

  • EBITDA

    26.31%

  • Operating

    21.23%

  • Pre-Tax

    21.8%

  • Net

    18.25%

  • FCF

    12.41%

Returns (5Yr Avg)

  • ROA

    16.33%

  • ROTA

    23.51%

  • ROE

    23.23%

  • ROCE

    23.59%

  • ROIC

    23.76%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $351.85

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $446.2M

  • Net Debt

    -$132.2M

  • Debt/Equity

    0.12

  • EBIT/Interest

    84.82

Growth (CAGR)

  • Rev 3Yr

    4.48%

  • Rev 5Yr

    10.23%

  • Rev 10Yr

    7.47%

  • Dil EPS 3Yr

    0.93%

  • Dil EPS 5Yr

    18.44%

  • Dil EPS 10Yr

    16.09%

  • Rev Fwd 2Yr

    2.33%

  • EBITDA Fwd 2Yr

    1.96%

  • EPS Fwd 2Yr

    -2.61%

  • EPS LT Growth Est

    6.32%

Dividends

  • Yield

  • Payout

    11.1%

  • DPS

    $0.79

  • DPS Growth 3Yr

    5.65%

  • DPS Growth 5Yr

    6.01%

  • DPS Growth 10Yr

    7.18%

  • DPS Growth Fwd 2Yr

    6.03%

NYSE:WST